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ABSTRACT 
 
 
Background 
Breast cancer is still a leading cause of cancer death among 
women. Thus, therapeutic alternatives from nature should 
be explored to lessen this burden. This is vital owing to the 
common occurrences of resistance in conventional 
therapies alongside their alarming side effects. 
 
 
Aims 
This study was carried out to investigate the inhibitory 
effect of Artonin E in female mice bearing 4T1 mammary 
tumour. 
 
Methods  
4T1 cells in 100µL PBS were injected into the right 
mammary fat pad of each female Balb/c mice aged between 
six to eight weeks. Treatment was commenced when the 
palpable tumour attained a size of 50–200mm
3
. The 
treatment groups included Artonin E, at dosages of 
25mg/kg, 50mg/kg and 100mg/kg per oral bi-weekly, 
10mg/kg of paclitaxel weekly and 5 percent tween 20 bi-
weekly. Tumour volume and body weight changes were 
recorded at the staging day and then twice every week 
throughout the study period. At the end of the study, the 
vital tissues were collected for histopathologcal assessment 
and blood samples were taken for serum biochemical 
analyses. 
 
Results  
From the results, the group treated with either 50mg/kg or 
100mg/kg of Artonin E showed a significant (p<0.05) 
reduction in tumour volume. Artonin E delayed quadruple 
tumour growth by more than five days in comparison to the 
untreated control group. Histopathology and biochemical 
analysis revealed no toxicity in the dosages of artonin E 
used in this study. Secondary tumour, which had 
metastasized to distant organs were seen to reduce upon 
treatment with Artonin E. 
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Conclusion 
With the capacity to reduce in vivo tumour growth, Artonin 
E has a great prospect to be developed into an anticancer 
agent. 
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What this study adds:  
1. What is known about this subject?  
Breast cancer is unfortunately the leading cause of cancer 
death among women.  
 
2. What new information is offered in this study? 
To the best of our knowledge, this is the first report on the 
in vivo efficacy of Artonin E in breast cancer. 
 
3. What are the implications for research, policy, or 
practice?  
The result of this study identifies Artonin E as a potential 
agent to treat breast cancer and reduce occurrence of 
metastasis.  
 
Background 
Breast cancer has been a threat to the female population 
and a leading cause of death among women.
1,2
 This 
encourages research into natural remedies to abate this 
disease. We had earlier reported the physicochemical 
properties of Artonin E, a phytochemical isolated from the 
root bark of Artocarpus elasticus,
3,4
 as well as its in vitro 
anti-breast cancer effect.
4-6
 While useful, in vitro 
experiments do not always translate to the complex, 
biological system, thus, the need for in vivo preclinical 
studies. In vivo experiments have been of great importance 
in cancer drug discovery
7
 and served as a guide to the 
establishment of a first-in-human trial.
8
 Today, 
demonstration of therapeutic efficacy and low toxicity in 
preclinical models is an essential component of the 
development of clinical drugs.
9,10
  
 
Animal models currently available for testing breast cancer 
drugs include: spontaneous, inducible, and syngeneic 
models of metastasis, xenografts of human breast cancer 
cell lines growing in immunodeficient mice, chemically 
induced mouse models, virally induced mouse models
11
 as 
well as humanized xenografts model of breast cancer which 
involves implantation of human tissue fragments like human 
bone fragments followed by orthotopic injection of human 
breast cancer cells to monitor migration of human cancer 
cells from the primary tumour environment to a human 
bone environment.
12
 The 4T1-model of breast cancer and 
metastasis was identified originally as a spontaneous breast 
cancer model in the BALB/c mouse strain.
13
 This murine 
breast tumour model has several characteristics that make 
it a suitable experimental animal model for human 
mammary cancer. Firstly, tumour cells are easily 
transplanted into the mammary gland so that the primary 
tumour grows in the anatomic correct site. Secondly, as in 
human breast cancer, 4T1 metastatic disease develops 
spontaneously from the primary tumour.
14
 Also, the 
progressive spread of 4T1 metastases to the draining lymph 
nodes and other organs is very similar to that of human 
mammary cancer
15
 and has been widely employed in breast 
cancer drug discovery.  
 
In vivo antitumour experiment can either be a tumour 
growth inhibition study (if treatment is initiated the day 
after or the day of tumour cell implant) or a tumour growth 
delay study (if treatment began with an established tumour 
nodule (50–200 mm
3
). According to Corbett et al. (1998),
16
 a 
stronger evidence of the clinical potential exist in the 
growth delay study than in the tumour growth inhibitory 
assay. Tumour growth delay also serves as a surrogate for 
disease progression.
17
 Indices or endpoints to measure 
antitumour effectiveness of tested agents include: 
measurement of tumour volume, tumour growth delay and 
doubling time, animal body weight throughout the study 
and the evaluation of biochemical and histopathological 
examinations.
18,19
 
 
This study is thus focused on the assessment of the 
antitumour effectiveness of Artonin E in 4T1 breast cancer 
cell challenged mice. 
 
Method 
Animals and environmental control 
Female Balb/c mice aged between six to eight weeks old 
were purchased from the animal research facility, Faculty of 
Veterinary Medicine, Universiti Putra Malaysia. The mice 
were housed in cages and allowed to acclimatize to the 
animal laboratory environment at 24±1˚C under a 12 h dark-
light cycle for one week before the commencement of the 
experiment. Pellets and water were provided ad libitum. 
Ethical approval for the conduct of this animal study was 
obtained from the Institutional Animal Ethical Committee, 
University of Malaya with the reference number 2015-
180804/PHARM/R/NMH. 
 
Preparation of cancer cells 
The 4T1 mouse breast cancer cell line was purchased from 
American Type Culture Collection (ATCC, USA). The cells 
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were maintained in DMEM and the cell cultured 
appropriately as previously reported.
4
 For collection of cells, 
the cells were tripsinized after washing with PBS and 
centrifuged at 125×g for 5 minutes. The cell pellet was 
counted using a hemocytometer and 1×10
6
 cells were 
resuspended in 100μL PBS for inoculation into the animals. 
 
Breast cancer induction 
Each mouse was anesthetized with an intraperitoneal 
injection of a mixture of Ketamine (90mg/kg) and Xylazine 
(10mg/kg) and a total of 110
6 
cells in 0.1ml PBS were 
implanted subcutaneously into the mammary fat pad (right 
flank) of each mouse. The implanted animals were 
examined every two days for tumour appearance. 
 
Experimental design, drug treatment and compound 
preparation 
Once the tumour became palpable (5 to 12 days post-
tumour induction) and the initial solid tumour established in 
the range of 50–200mm
3
, when measured with an 
electronic vernier caliper, the female BALB/c mice were 
randomized into seven groups consisting of five animals 
each (n=5). Group 1 comprised of untreated normal, healthy 
mice and served as the negative control (animals without 
the breast cancer burden). Group 2 comprised of mice 
induced to develop breast cancer and served as the breast 
cancer control but without any treatment. Group 3 
comprised of mice induced to develop breast cancer, but 
treated with the vehicle and served as the breast cancer 
vehicle control group, while groups 4, 5 and 6 were breast 
cancer mice treated bi-weekly with 25mg/kg, 50mg/kg and 
100mg/kg body weight of Artonin E dissolved in 5 percent 
Tween 20 (Sigma Aldrich, USA) respectively. Group 7 was 
treated intraperitoneally with 10mg/kg body weight of 
Paclitaxel once every week.
20
 Paclitaxel is a naturally 
derived anticancer agent, thought to inhibit tumours of the 
breast, lungs and ovary by binding to tubulin.
21
 The working 
solution of this paclitaxel (Taxol, Bristol-Myers Squibb Co., 
Princeton, NJ) was prepared by diluting the drug in normal 
saline (NS) to a dose of 10mg/kg in 150µl per injection, once 
a week for four weeks. The Artonin E treatments were given 
orally for four consecutive weeks to the animals through 
gastric intubations. The oral route was chosen for Artonin E 
since it is the intended route, being non-invasive and had 
proved a good bioavailability in an earlier in silico studies.
4 
On the other hand paclitaxel was administered 
intraperitoneally based on availability, especially as the 
objective of the work was focussed on therapeutic efficacy 
of Artonin E and not the former.  
 
The concentrations of Artonin E chosen were based on 
preliminary acute toxicity testing (unpublished data) where 
no clinical sign of toxicity was observed in the mice group 
treated with 1,000mg/kg of Artonin E. The schedule of 
Artonin E treatment was similar to that adopted by Ibrahim 
et al.
22
 and was used based on the recommendation of 
Hollingshead.
17
 Paclitaxel dose and treatment schedule 
were based on a previous report by Liao et al.
20  
 
Measurement of tumour growth delay and inhibition 
To assess the antitumour effect of Artonin E in breast 
cancer bearing mice, the growth of the solid tumours was 
monitored using in situ caliper measurements to determine 
the tumour volume. Tumour volumes (mm
3
) were 
calculated from the measurements (mm) of two 
perpendicular dimensions length (L) and width (W) using 
the formula for a prolate ellipsoid
23
 as follows:- 
Volume (mm
3
)=L/2W
2 
 
 
The measurement was done before the treatment was 
initiated (staging day) and then twice every week for the 
study period by a scientist who was blinded to the various 
treatment as well as the study at large. Some efficacy 
endpoints were utilized in assessing the antitumour effects 
as recommended by the Developmental Therapeutics 
Program of the US National Cancer Institute 
(http://dtp.nci.nih.gov). This included the relative tumour 
volume, percent test/control (percent T/C), tumour weights 
calculated for each day that tumours were measured and 
tumour growth delay. 
 
The relative tumour volume (VT/V0) was calculated for every 
tumour volume at any given time (VT) against the tumour 
volume at staging day (V0). The relative tumour volume 
(RTV) – time profile for each group was plotted and tumour 
growth delay in attaining a specified number of doublings 
(quadruple) compared to the untreated control was 
determined (i.e. the time taken for the relative tumour 
volume to increase fourfold (RTV4).  
 
The RTV was used to calculate the tumour growth inhibition 
(ratio between the treated (T) and control (C) tumours) as 
an indication of drug efficacy
10
 using the following formulas: 
T/C per cent=RTVT/RTVC100 
 
To evaluate toxicity, body weight was measured twice a 
week and the relative body weight (BWT/BW0) was 
calculated for every body weight at any given time (VT) 
against the body weight at staging day (V0). The relative 
body weight – time profile for each group was plotted. 
 
At the end of the study, all the mice were euthanised using 
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an overdose of Ketamine and Xylazine (180mg/kg and 
20mg/kg respectively). The liver, kidney, spleen, lungs 
tissues were collected for histopathology assessment and 
blood samples were taken from mice after the course of 
treatment for biochemistry analysis.  
 
Biochemical analysis 
Blood samples from at least three mice representative of 
each animal group were collected in separate tubes with 
heparin as anticoagulant and centrifuged (Hettich zent-
EBA20, Germany) at 1500×g for 10 minutes, serum was 
obtained, separated into clean new tubes and stored at ˗ 
20˚C until analyzed. The liver enzymes, Alanine amino 
transferase (ALT), Alkaline phosphatase (ALT), creatinine 
and lactate dehydrogenase were analyzed using standard 
diagnostic kits (Roche) in an automatic biochemical analyzer 
(Hitachi 902, Japan). 
 
Haematoxylin and Eosin (H&E) histology staining 
 The excised organs were cut into sections of about 0.5cm
2
 
sizes and fixed in 10 per cent formalin for at least 48 h, 
embedded in paraffin wax (Leica EG1160, Germany) and the 
blocks trimmed and sectioned to about 5×5×4μm size using 
a microtome (Leica RM2155). The tissue sections were 
mounted on glass slides using a hot plate (Leica HI1220, 
Germany) and subsequently treated with alcohol. The 
processed tissues were rinsed with tap water and finally 
stained with the Harris’s haematoxylin and eosin (H & E) 
(Luna, 1968) and examined under a light microscope (Nikon, 
Japan). 
 
Statistical analysis 
Each of the animal group contained five mice to enable 
statistical analysis. The biochemical and histopathological 
analysis were done in triplicate and the results expressed as 
mean ± standard error of mean. The level of significance 
difference between the mean of each treatment group and 
the control for each of the investigated efficacy indices was 
determined using the unpaired two-tailed Student’s t-test 
for independent samples; P-values <0.05 were considered 
to be statistically significant. Analysis of variance was also 
employed where necessary to compare the treatment 
groups per day with the untreated cancer control group 
followed by Turkey’s post hoc test. All the statistical analysis 
was carried out in the GraphPad prism 5.0 (GraphPad 
Software Inc., La Jolla, CA, USA). 
 
Results 
Artonin E inhibits the growth of Breast cancer in vivo 
From the results, there was a significant (p<0.05) decrease 
in the relative tumour volumes of mice treated with 50 and 
100mg/kg of Artonin E. The standard agent, paclitaxel also 
showed a significant decrease in the relative tumour 
volume. On the other hand, the mice group treated with 
25mg/kg of Artonin E was not significantly different (p>0.05) 
from the control in terms of the tumour volume (Figure 1). 
The mice group treated with the vehicle of dissolution, 5 per 
cent Tween 20, showed no significance (p>0.05) difference 
in mammary tumour volume when compared with the 
untreated control mice. Hence, the cancer control animals 
were used to compare treatment effect of Artonin E 
treatment.The variability in the tumour volumes of the mice 
at the staging day before any therapeutic intervention is 
depicted in Figure 2. 
 
Artonin E delayed in vivo breast cancer tumour quadruple 
growth  
The effect of Artonin E in delaying mice mammary gland 
tumours from reaching 400 per cent of the first palpable 
tumour volume was calculated after extrapolation from 
Figure 1 From the results, the control group took nine days 
to increase four times its initial volume from the staging 
day. Mice treated with 25mg/kg of Artonin E took 
approximately 10 days, while groups treated with 50 and 
100mg/kg of Artonin E took approximately 11 and 14 days 
to reach the specified relative tumour volume, respectively. 
The differences in days taken by the treatment group to 
reach the quadruple volume as extrapolated from Figure 1 
was subtracted from the delay experienced by the 
untreated control groups and presented in Table 1 
 
Artonin E induced tumour growth inhibition in vivo 
Another index of assessing in vivo antitumour activity is the 
tumour growth inhibition (%T/C). The results were 
compared with the arbitruary cut-off for in vivo growth 
inhibition (Table 2) reported by Wu.
24
 From the results, 
100mg/kg of Artonin E had an inhibition of 38 per cent, 
regarded as having intermediate in vivo antitumour activity. 
The groups treated with 50mg/kg of Artonin E had a T/C 
value of 57 per cent and the 25mg/kg of Artonin E treated 
group had 88 per cent value which were both considered as 
inactive (Tables 2 and 3). 
 
Body weight of Artonin E treated mammary gland tumour-
bearing mice 
The relative body weight changes of the mice in this study 
were used as a measure of toxicity to Artonin E. Kruczynski 
et al.,
25
 reported that decrease in body weight exceeding 15 
per cent is considered as toxicity due to the treatment. In 
this study, generally, there was no observed weight loss in 
the Artonin E treated mice in comparison to the untreated 
tumour-bearing mice (Figure 3). However, after 24 days of 
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treatment, mice treated with 50 and 100mg/kg of Artonin E 
showed lower relative weight gain compared to those 
treated with 25mg/kg of Artonin E.  
 
Effect of Artonin E on serum biochemical parameters.  
In this study ALT, ALP and LDH were chosen as the serum 
liver enzymes and creatinine as an indicator for renal 
function. The study revealed a significant (p<0.05) elevation 
of the liver-specific enzyme ALT in the untreated tumour 
bearing mice in comparison to. treated groups (Table 4). 
There was a marked increase in LDH in the tumour-bearing 
mice, which decreased upon treatment with Artonin E. 
 
Histopathology 
The livers of mice with 4T1 cell-induced mammary gland 
showed numerous mutifocal clusters of neoplastic cells, 
suggesting metastasis of mammary glands tumour (primary 
site) to the liver. The tumour area also contained numerous 
leucocytes, predominantly made up of neutrophils and 
resident Kupffer cells in untreated tumour-bearing mice 
(Figure 4). Treatment of mammary gland tumour with 
Artonin E (3C-D) showed reduced metastasis to the liver. 
This was observed by the fewer neoplastic cell clusters 
observed in the livers of mice treated with 50 and 100mg/kg 
Artonin E in comparison to those treated with 25mg/kg of 
Artonin E.  
 
The lungs of mice with untreated 4T1 induced mammary 
gland tumour showed multifocal areas of lung consolidation 
comprising of metastatic tumour cells, numerous 
lymphocyte and granulocyte infiltration (Figure 5). There 
were fewer observed metastatic cells following treatment 
owing to apoptosis shown by the altered and irregular 
neoplastic cell membrane. A restoration of the lung 
morphology was observed following Artonin E treatment, as 
evidenced by the high number of alveoli (Figure 5C-5E).  
 
The kidneys of the mice were also examined (Figure 6). Both 
the treated and untreated kidney tissues showed normal 
tissue morphology. The glomerular architecture and 
epithelial lining of the tubules also appeared normal in all 
groups of mice with no observable signs of toxicity.  
 
Discussion 
It is vital to investigate the in vivo growth inhibition of a 
potential anticancer agent. This is because a compound can 
possess good in vitro growth inhibitory properties but fails 
to reproduce a similar effect in vivo within the full 
complexity of the tumour microenviroment. Consequently, 
in vivo studies, which are usually preclinical trials, have 
played a crucial role in nearly every medical breakthrough 
and has been of great importance in cancer drug 
discoveries.
7
 The 4T1-induced murine mammary gland 
tumour is an excellent model for human breast cancers 
because it is aggressive and easily metastasizes.
14,15
 Thus, in 
this study, the female Balb/c mice bearing 4T1 mammary 
gland tumour were used to investigate the efficacy of 
Artonin E as a potential antitumour agent.  
 
There are several indices for efficacy evaluation in an in vivo 
model recommended by the Developmental Therapeutics 
Program of the US National Cancer Institute 
(http://dtp.nci.nih.gov). One of them is the relative tumour 
volume. In this study, the relative tumour volume (VT/V0) 
was calculated for every tumour at any given time (VT) 
against the tumour volume at staging day (V0).
26
 From the 
results, Artonin E appeared to produce its antitumoural 
effect in a dose-dependent manner. Mice treated with 
Artonin E, at dosages of 50 and 100mg/kg, showed 
significantly reduced tumour volume. However, there was 
no significant reduction in the relative mammary tumour 
volume in mice treated with 25mg/kg of Artonin E. This 
suggested that 25mg/kg per os of Artonin E was too low for 
the compound to reach therapeutic concentration at the 
tumour site. The failure to produce effect at this 
concentration may as well be attributed to extensive first 
pass effect
27
 which might have caused a decrease in the 
systemic availability of Artonin E below the in silico 
predicted oral bioavailability of 88 per cent.
4
 The 
multiplexity of the tumour micrenviroment could as well 
render the dose too low for therapeutic effect. Thus, 
Artonin E, at appropriate dosages when administered orally, 
can produce antitumour effects. This oral method of 
delivery is ideal for therapeutic compound because it is non-
invasive, convenient and patient-compliant.  
 
Another modality to assess in situ tumour treatment effect 
is the determination of tumour growth delay in reaching a 
specified number of doublings.
17
 The rate of growth delay 
was observed to be a function of dose in the treated mice. 
By direct extrapolation from the graph, at the highest dose 
of Artonin E, the mice tumour took approximately 14 days 
to reach a quadruple size from its staging day volume in 
comparison to the untreated mice that took nine days. 
Thus, 100mg/kg of Artonin E delayed qudruple tumour 
growth by approximately five days compared to untreated 
control. 
  
Tumour growth assessment was also done by assessing the 
ratio of the relative tumour volume of Artonin E-treated 
mice to the relative tumour volume of the untreated mice 
using the arbitrary tumour growth inhibition (T/C) cut-off. 
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The T/C is a rough measure of growth inhibition. In this 
study, on the 28
th
 day of the study period, 50mg/kg of 
Artonin E produced a T/C value of 57 per cent exceeding the 
antitumour arbitrary cut-off of 45 per cent reported in 
earlier studies.
24,28,29
 Artonin E at a dose of 100mg/kg 
showed greatly improved antitumour activity with a T/C of 
38 per cent. However, Artonin E at this dose still had 
intermediate level antitumour activity.
24
  
 
Chemotherapy can cause toxicity that can be envisaged 
from the relative body weight measurement. In the course 
of this study, the body weight of each mouse in each of the 
groups was measured and recorded. From the results, there 
was no significant change in the body weight of Artonin E-
treated mice when compared to the untreated mice. It is 
suggested that decrease in body weight exceeding 15 per 
cent as a result of treatment is considered an indicator of 
toxicity.
25
 Fortunately, none of the Artonin E treated mice 
showed significant body weight loss, indicating that it did 
not cause toxicity at doses used in this study.  
 
To determine the effect of Artonin E treatment on key 
organs, serum biochemical parameters were evaluated. The 
ALT, ALP, and LDH were chosen as the serum liver enzymes 
and creatinine as an indicator for renal function. The serum 
enzymes are used as indicators of liver damage and toxicity 
in chemotherapy.
30
 The concentrations of these enzymes 
are only significant when they are elevated. Decreases in 
these parameters are only a reflection of diurnal and daily 
fluctuations. ALT is a cytoplasmic enzyme in which the 
serum activity is increased due to leakage across damaged 
cytoplasmic membranes. This study showed that the liver-
specific enzyme ALT was only marginally (p>0.05) elevated 
in the tumour bearing mice treated with Artonin E. This 
indicated that there was no rampant hepatic damage 
related to the treatment.
31
 However, there was a significant 
higher level of the enzyme in the untreated tumour bearing 
mice and the vehicle control mice compared to healthy mice 
without tumour burden. This elevation is suggested to be 
associated with the degeneration of hepatocytes as a result 
of the metastatic breast cancer.
32
  
 
The level of LDH increased significantly in the untreated 
mice. This enzyme is often used as a non-specific indicator 
of cancers and its increase in serum is due to the 
progression of mammary gland cancer and liver 
metastasis.
33
 LDH concentration increased in mice with 
untreated mammary gland tumour and mildly decreased 
upon treatment. The creatinine level was not elevated, 
indicating that the kidney was neither affected by the 
tumour nor damaged by Artonin E treatment.  
To further verify the antitumour activity of Artonin E, the 
liver, lungs and kidney were subjected to histopathological 
examination. The murine 4T1-induced mammary gland 
tumour was shown to have spontaneously metastasized to 
the liver and lungs within days of tumour inoculation.
13
 The 
liver tissue from the tumour bearing mice showed 
abundance of infiltrating neoplastic cells as well as 
leukocytes. The hepatocytes also showed cellular 
vacuolation. The neoplastic infiltrations and hepatocyte 
degeneration were reflected in the elevated serum ALT in 
this group of mice. Upon increasing the concentration of 
Artonin E in the treatment of the mammary gland tumour, 
the clusters of neoplastic cells in the liver reduced. It can, 
thus be deduced that treatment with Artonin E may have 
prevented massive metastasis or Artonin E had also killed 
cancer cells in the hepatic tissue.  
 
The histopathology of the lungs of untreated tumour 
bearing mice showed abundance of metastatic breast 
cancer cells with numerous lymphocytes and granulocytes. 
Breast cancer metastasis, has been reported to frequently 
metastasize to the lungs resulting in the poor survival of 
patients. Pulmonary metastasis of mammary tumours had 
been reported to be one of the main causes of death.
34
 
From the results, therapeutic intervention with increasing 
doses of Artonin E reduced the metastasis and inflammation 
in the lungs. The lungs of Artonin E treated mice showed 
restoration of normal morphology.  
 
The kidneys from the mice with mammary gland tumour 
treated with Artonin E did not show any renal morphology 
abnormality. This suggested that Artonin E, at all dosages 
used in this study was not nephrotoxic. This observation is 
collaborated by lack of increase of serum creatinine, a 
parameter used for assessment of renal function.  
 
Conclusion 
Artonin E significantly inhibited the in vivo growth of the 
aggressive 4T1-induced mammary gland tumour in mice in a 
dose-dependent manner. Additionally, Artonin E reduced 
the rampant metastasis of this aggressive tumour without 
causing any observed toxicity. Thus, Artonin E shows great 
promise not only as a potential antimammary gland tumour 
agent but also as a potential antimetastasis agent.  
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Figure 1: Effect of Artonin E on tumor volume in Balb/c mice induced to develop mammary gland tumour with 4T1 cells. 
Each point represents means±SEM (n=5/group) of tumour volume relative to staging day. CC=cancer control (untreated 
positive control), VC=vehicle control (treated with the vehicle, 5%Tween 20) and PTX=paclitaxel. Differences are 
statistically significant with *(p<0.05) when compared to the cancer control at each given day. The dotted line indicates 
time taken for tumour to reach quadruple growth 
 
 
Figure 2: Variability in tumour volume of tumour bearing mice randomised into the various study groups at the staging day 
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Figure 3: Relative body weight of mice treated with Artonin E. Each point represents means±SEM (n=5/group). Body 
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weight changes were not significant from the negative control 
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Figure 4: Liver from Balb/c with 4T1 cell induced mammary gland tumour treated with (C) 25mg/kg, (D) 50mg/kg and (E) 
100mg/kg of Artonin E. (A) is healthy mice, (B) is untreated tumourous mice (H & E) 
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Figure 5: Lungs from Balb/c mice with 4T1 cell induced mammary gland tumour treated with (C) 25mg/kg, (D) 50mg/kg 
and (E) 100mg/kg of Artonin E. (A) is healthy mice, (B) is untreated tumourous mice (H & E) 
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Figure 6: Kidney from Balb/c mice with 4T1 cell induced mammary gland tumour treated with (C) 25mg/kg, (D) 50mg/kg 
and (E) 100mg/kg of Artonin E. (A) is healthy mice, (B) is untreated tumourous mice (H & E) 
 
 
 
Table 1: Tumour growth delay in artonin E treated breast cancer bearing mice 
 
Compound Dose (mg/kg) Quadruple growth delay (T-C) (Days) 
Artonin E 
25 0.7 
50 1.3 
100 5.3 
Paclitaxel 10 10.8 
T and C represent time taken for treated tumours to reach 400% of the first palpable tumour volume, while C represents the 
number of days for the untreated group to reach similar tumour volume. T-C is the difference in days between the treated 
and untreated group in achieving 400% of the firat palpable tumour volume. The first palpable tumour volume was the initial 
volume of tumour before treatment was commenced 
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Table 2: In Vivo Antitumor Growth Inhibition Rating 
 
Measurement Cutoff point Activity rating 
T/C ≤15% Highly active 
 >15% and ≤45% Intermediate 
active 
 >45% Inactive 
 
Table 3. T/C* values for Artonin E treated murine mammary tumour 
 
Dose 
Experimental Period (day) 
0 4 8 12 16 20 24 28 
T/C values 
25mg/kg Artonin E 100 103 93 90 87 83 79 81 
50mg/kg Artonin E 100 98 86 82 69 63 59 56 
100mg/kg Artonin E 100 96 78 63 44 44 40 38 
10mg/kg Paclitaxel 100 96 86 56 34 27 25 26 
Value was calculated from the mean relative tumour volume of treated mice and control, untreated mice 
 
Table 4: Serum biochemical parameters of mammary gland tumor-bearing mice treated with Artonin E 
 
Treatment ALT (U/L) ALP (U/L) LDH (U/L) Creatinine(µmol/L) 
Healthy Control 43.0±1.2 116.5±7.8 273.3±25.1 39.5±0.9 
Cancer Control  125.7
a
±47.2  54.0±1.2  2095.3
a
±30.9  36.7±2.9  
Vehicle (Control) (100µL 
5% Tween 20) 
112.9
a
±3.0  41.5±3.2  2107.5
a,b
±7.2
 
 42.0±0.6  
25mg/kg Artonin E 75.7±0.2  53.5±3.8  1779.5
a,
±77.1  42.1±1.0  
50mg/kg Artonin E 39.3
a
±3.0  52.0±5.0  1835.7
a,
±105.1  29.7±1.9  
100mg/kg Artonin E 53.0
a
±2.1  57.0±5.7  1945.0
a
±36.7  43.0±0.6
 
 
10mg/kg Paclitaxel 59.2
a
±4.8  68.5
ac
±3.3  1965.5
a
±8.9  30.5±5.5  
Values are mean±SEM. a=significant elevation between treatment and healthy control, b=significance between treatment 
and cancer control and c=significance between treatments and vehicle control. 
ALT=Alanine aminotransferase; ALP=Alkaline phosphatase; LDH= Lactate dehydrogenase 
